Cargando…
Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies
Multiple studies have investigated the role of blood circulating proteins in COVID-19 disease using the Olink affinity proteomics platform. However, study inclusion criteria and sample collection conditions varied between studies, leading to sometimes incongruent associations. To identify the most r...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821526/ https://www.ncbi.nlm.nih.gov/pubmed/35145507 http://dx.doi.org/10.3389/fimmu.2021.781100 |
_version_ | 1784646419896860672 |
---|---|
author | Suhre, Karsten Sarwath, Hina Engelke, Rudolf Sohail, Muhammad Umar Cho, Soo Jung Whalen, William Alvarez-Mulett, Sergio Krumsiek, Jan Choi, Augustine M. K. Schmidt, Frank |
author_facet | Suhre, Karsten Sarwath, Hina Engelke, Rudolf Sohail, Muhammad Umar Cho, Soo Jung Whalen, William Alvarez-Mulett, Sergio Krumsiek, Jan Choi, Augustine M. K. Schmidt, Frank |
author_sort | Suhre, Karsten |
collection | PubMed |
description | Multiple studies have investigated the role of blood circulating proteins in COVID-19 disease using the Olink affinity proteomics platform. However, study inclusion criteria and sample collection conditions varied between studies, leading to sometimes incongruent associations. To identify the most robust protein markers of the disease and the underlying pathways that are relevant under all conditions, it is essential to identify proteins that replicate most widely. Here we combined the Olink proteomics profiles of two newly recruited COVID-19 studies (N=68 and N=98) with those of three previously published COVID-19 studies (N=383, N=83, N=57). For these studies, three Olink panels (Inflammation and Cardiovascular II & III) with 253 unique proteins were compared. Case/control analysis revealed thirteen proteins (CCL16, CCL7, CXCL10, CCL8, LGALS9, CXCL11, IL1RN, CCL2, CD274, IL6, IL18, MERTK, IFNγ, and IL18R1) that were differentially expressed in COVID-19 patients in all five studies. Except CCL16, which was higher in controls, all proteins were overexpressed in COVID-19 patients. Pathway analysis revealed concordant trends across all studies with pathways related to cytokine-cytokine interaction, IL18 signaling, fluid shear stress and rheumatoid arthritis. Our results reaffirm previous findings related to a COVID-19 cytokine storm syndrome. Cross-study robustness of COVID-19 specific protein expression profiles support the utility of affinity proteomics as a tool and for the identification of potential therapeutic targets. |
format | Online Article Text |
id | pubmed-8821526 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88215262022-02-09 Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies Suhre, Karsten Sarwath, Hina Engelke, Rudolf Sohail, Muhammad Umar Cho, Soo Jung Whalen, William Alvarez-Mulett, Sergio Krumsiek, Jan Choi, Augustine M. K. Schmidt, Frank Front Immunol Immunology Multiple studies have investigated the role of blood circulating proteins in COVID-19 disease using the Olink affinity proteomics platform. However, study inclusion criteria and sample collection conditions varied between studies, leading to sometimes incongruent associations. To identify the most robust protein markers of the disease and the underlying pathways that are relevant under all conditions, it is essential to identify proteins that replicate most widely. Here we combined the Olink proteomics profiles of two newly recruited COVID-19 studies (N=68 and N=98) with those of three previously published COVID-19 studies (N=383, N=83, N=57). For these studies, three Olink panels (Inflammation and Cardiovascular II & III) with 253 unique proteins were compared. Case/control analysis revealed thirteen proteins (CCL16, CCL7, CXCL10, CCL8, LGALS9, CXCL11, IL1RN, CCL2, CD274, IL6, IL18, MERTK, IFNγ, and IL18R1) that were differentially expressed in COVID-19 patients in all five studies. Except CCL16, which was higher in controls, all proteins were overexpressed in COVID-19 patients. Pathway analysis revealed concordant trends across all studies with pathways related to cytokine-cytokine interaction, IL18 signaling, fluid shear stress and rheumatoid arthritis. Our results reaffirm previous findings related to a COVID-19 cytokine storm syndrome. Cross-study robustness of COVID-19 specific protein expression profiles support the utility of affinity proteomics as a tool and for the identification of potential therapeutic targets. Frontiers Media S.A. 2022-01-25 /pmc/articles/PMC8821526/ /pubmed/35145507 http://dx.doi.org/10.3389/fimmu.2021.781100 Text en Copyright © 2022 Suhre, Sarwath, Engelke, Sohail, Cho, Whalen, Alvarez-Mulett, Krumsiek, Choi and Schmidt https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Suhre, Karsten Sarwath, Hina Engelke, Rudolf Sohail, Muhammad Umar Cho, Soo Jung Whalen, William Alvarez-Mulett, Sergio Krumsiek, Jan Choi, Augustine M. K. Schmidt, Frank Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies |
title | Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies |
title_full | Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies |
title_fullStr | Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies |
title_full_unstemmed | Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies |
title_short | Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies |
title_sort | identification of robust protein associations with covid-19 disease based on five clinical studies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821526/ https://www.ncbi.nlm.nih.gov/pubmed/35145507 http://dx.doi.org/10.3389/fimmu.2021.781100 |
work_keys_str_mv | AT suhrekarsten identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT sarwathhina identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT engelkerudolf identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT sohailmuhammadumar identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT chosoojung identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT whalenwilliam identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT alvarezmulettsergio identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT krumsiekjan identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT choiaugustinemk identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies AT schmidtfrank identificationofrobustproteinassociationswithcovid19diseasebasedonfiveclinicalstudies |